Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

by Luke, Jason J.
Published in Oncologist (2019)

Considering adjuvant therapy for stage II melanoma

by Poklepovic, Andrew S., Luke, Jason J.
Published in Cancer (2019)

Dendritic cells, the T cell-inflamed tumor microenvironment and immunotherapy treatment response

by Garris, Christopher S., Luke, Jason J.
Published in Clin Cancer Res (2020)

Improving Quality and Addressing the Rising Costs of Cancer Care: Two Birds, One Stone

by Luke, Jason, Mirkin, Joshua, Bach, Peter
Published 2011

Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma

by Luke, Jason J., Schwartz, Gary K.
Published 2013

Advances in the Systemic Treatment of Cutaneous Sarcomas

by Luke, Jason J, Keohan, Mary-Louise
Published 2012

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

by Luke, Jason J., Hodi, F. Stephen
Published 2013

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

by Luke, Jason J, Ott, Patrick A
Published 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

by Luke, Jason J., Ott, Patrick A.
Published in Oncotarget (2015)

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

by Sweis, Randy F., Luke, Jason J.
Published in Pharmacol Res (2017)

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development

by Olson, Daniel J, Luke, Jason J
Published in Immunotherapy (2019)

Improving therapy in metastatic uveal melanoma by understanding prior failures

by Olson, Daniel J., Luke, Jason J.
Published in Oncoscience (2020)

Toll-Like Receptor 9 Agonists in Cancer

by Karapetyan, Lilit, Luke, Jason J, Davar, Diwakar
Published in Onco Targets Ther (2020)

Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types

by Bao, Riyue, Stapor, Daniel, Luke, Jason J.
Published in Genome Med (2020)

Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis

by Labadie, Brian W., Bao, Riyue, Luke, Jason J.
Published in Clin Cancer Res (2018)

PD-1 Blockade in Chinese versus Western Patients with Melanoma

by Shoushtari, Alexander N., Bao, Riyue, Luke, Jason J.
Published in Clin Cancer Res (2020)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

by Trojaniello, Claudia, Luke, Jason J., Ascierto, Paolo A.
Published in Front Oncol (2021)

ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

by Bao, Riyue, Hernandez, Kyle, Huang, Lei, Luke, Jason John
Published in J Immunother Cancer (2020)

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a ran...

by Luke, Jason J., Zha, Yuanyuan, Matijevich, Karen, Gajewski, Thomas F.
Published in J Immunother Cancer (2016)

High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

by Zielinski, Jessica M., Luke, Jason J., Guglietta, Silvia, Krieg, Carsten
Published in Front Immunol (2021)